Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmune-l...
Guardado en:
Autores principales: | Zoe Apalla, Chryssoula Papageorgiou, Aimilios Lallas, Florentina Delli, Christina Fotiadou, Christina Kemanetzi, Elizabeth Lazaridou |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Mattioli1885
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d217a6d3c37346e39c2b74f9ea6109c8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Wolfram Samlowski, et al.
Publicado: (2021) -
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
por: Selina K. Wong, et al.
Publicado: (2021) -
Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma
por: Marc-Oliver Grimm, et al.
Publicado: (2021) -
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
por: Pramod Savarapu, et al.
Publicado: (2021) -
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Morten Fink, et al.
Publicado: (2021)